Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
Mirikizumab for treating moderately to severely active ulcerative colitis
Mirikizumab is a p19-directed antibody against interleukin-23.
It has been shown that mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis (1).
NICE state:
Mirikizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if:
The NICE committee note "..TNF-alpha inhibitors are the most used biological treatments for moderately to severely active ulcerative colitis. When TNF-alpha inhibitors have not worked, or are not tolerated, usually people are offered vedolizumab or ustekinumab. Mirikizumab is another biological treatment that would be offered to the same population as these 2 treatments.
Clinical trial evidence shows that mirikizumab is more effective than placebo for treating moderately to severely active ulcerative colitis. But there are no clinical trials directly comparing mirikizumab with vedolizumab or ustekinumab. An indirect comparison suggests that all 3 treatments are similarly effective.."
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.